Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis

The intestinal microbiota has been linked to the development and prevalence of steatohepatitis in humans. Interestingly, steatohepatitis is significantly lower in individuals taking a plant‐based, low‐animal‐protein diet, which is thought to be mediated by gut microbiota. However, data on causality...

Full description

Saved in:
Bibliographic Details
Published inHepatology communications Vol. 4; no. 11; pp. 1578 - 1590
Main Authors Witjes, Julia J., Smits, Loek P., Pekmez, Ceyda T., Prodan, Andrei, Meijnikman, Abraham S., Troelstra, Marian A., Bouter, Kristien E.C., Herrema, Hilde, Levin, Evgeni, Holleboom, Adriaan G., Winkelmeijer, Maaike, Beuers, Ulrich H., Lienden, Krijn, Aron‐Wisnewky, Judith, Mannisto, Ville, Bergman, Jacques J., Runge, Jurgen H., Nederveen, Aart J., Dragsted, Lars O., Konstanti, Prokopis, Zoetendal, Erwin G., Vos, Willem, Verheij, Joanne, Groen, Albert K., Nieuwdorp, Max
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.11.2020
John Wiley and Sons Inc
Wolters Kluwer Health/LWW
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The intestinal microbiota has been linked to the development and prevalence of steatohepatitis in humans. Interestingly, steatohepatitis is significantly lower in individuals taking a plant‐based, low‐animal‐protein diet, which is thought to be mediated by gut microbiota. However, data on causality between these observations in humans is scarce. In this regard, fecal microbiota transplantation (FMT) using healthy donors is safe and is capable of changing microbial composition in human disease. We therefore performed a double‐blind randomized controlled proof‐of‐principle study in which individuals with hepatic steatosis on ultrasound were randomized to two study arms: lean vegan donor (allogenic n = 10) or own (autologous n = 11) FMT. Both were performed three times at 8‐week intervals. A liver biopsy was performed at baseline and after 24 weeks in every subject to determine histopathology (Nonalcoholic Steatohepatitis Clinical Research Network) classification and changes in hepatic gene expression based on RNA sequencing. Secondary outcome parameters were changes in intestinal microbiota composition and fasting plasma metabolomics. We observed a trend toward improved necro‐inflammatory histology, and found significant changes in expression of hepatic genes involved in inflammation and lipid metabolism following allogenic FMT. Intestinal microbial community structure changed following allogenic FMT, which was associated with changes in plasma metabolites as well as markers of . Conclusion: Allogenic FMT using lean vegan donors in individuals with hepatic steatosis shows an effect on intestinal microbiota composition, which is associated with beneficial changes in plasma metabolites and markers of steatohepatitis.
Bibliography:These authors contributed equally to this work.
Supported by Hartstichting (Grant/Award No. 2012‐03) and Fondation Leducq (Grant/Award No. 17CVD01).
Clinical Trial Registration – Trial NL4189 (NTR4339).
Potential conflict of interest: Dr. Aron‐Wisnewsky received grants from the Bettencourt Schueller Foundation. Dr. Nieuwdorp and Dr. de Vos own stock in, consult for, and has intellectual property rights in Caelus Health. He consults for Kaleido. None of these are directly relevant to the current paper.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2471-254X
2471-254X
DOI:10.1002/hep4.1601